Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
May 08, 2017
- Translarna™ first quarter net sales of $26.4M representing 40% year-over-year growth -
- Full-year 2017 Translarna net sales guidance increased to $115 to $130M -
- EMFLAZATM for the treatment of Duchenne muscular dystrophy planned to launch in the coming weeks -
Additional Formats
Apr 26, 2017
SOUTH PLAINFIELD, N.J. , April 26, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 21, 2017 it approved non-statutory stock options to purchase 266,400 shares of its common stock to 32 new employees. The awards were made pursuant to the NASDAQ inducement
Additional Formats
Apr 24, 2017
SOUTH PLAINFIELD, N.J. , April 24, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter financial results and provide an update on the company's business and outlook on Monday, May 8, 2017 at
Additional Formats
Apr 20, 2017
SOUTH PLAINFIELD, N.J. , April 20, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has completed its acquisition of all rights to Emflaza™ (deflazacort) for the treatment of Duchenne muscular dystrophy (DMD) in the U.S. Execution of the asset purchase agreement
Additional Formats
Apr 10, 2017
SOUTH PLAINFIELD, N.J. , April 10, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs , Chief Financial Officer, will be leaving the company in mid-May 2017 to return to the finance sector, joining RBC Capital Markets as Managing Director where he will
Additional Formats
Mar 16, 2017
- $81.4M in Translarna net sales, a 142% increase vs. 2015 -
- October 24th PDUFA target date for Translarna nmDMD NDA -
- SMA program actively enrolling patients across SUNFISH and FIREFISH trials -
- Translarna 2017 net sales guidance of $105M to $125M -
Additional Formats
Mar 16, 2017
- Emflaza is the first treatment approved in the U.S. for DMD patients 5 years and older, regardless of genetic mutation
- Aligns with PTC's mission and commitment to the DMD community
- $140 million upfront consideration (comprised of cash and PTC common stock) plus potential contingent payments based on net sales and single milestone payment
- PTC to host investor conference call today, March 16, 2017 at 8:30 am ET
Additional Formats
Mar 13, 2017
SOUTH PLAINFIELD, N.J. , March 13, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2016 financial results and provide an update on the company's business and outlook on
Additional Formats
Mar 06, 2017
- FDA has assigned a PDUFA date of October 24, 2017 -
Additional Formats
Mar 02, 2017
- ACT CF trial missed primary and secondary endpoints -
- Company to host conference call today, March 2nd at 9:00 am ET -
Additional Formats